Seattle Genetics (SGEN) has reached and passed one of our price targets from our May 4 review. We wrote that "the business of finding blockbuster cancer drugs can be feast or famine but it looks like SGEN is doing it right. Trade SGEN from the long side risking a close below $135 for now. We have price targets from $180 on up to $286."
SGEN touched $200 today so let's check the charts again.